One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.

The Food and Drug Administration (FDA) has approved a new presentation of Selarsdi ™ (ustekinumab-aekn), a biosimilar to Stelara ® (ustekinumab), expanding the product’s indications to include ...

psoriatic arthritis, and adults with chronic moderate-to-severe plaque psoriasis. In clinical trials, the most common adverse effect of this treatment was injection site reaction (ISR).

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritisTwo trials for ...

Some people come home from a beach vacation and notice their skin looks clear and glowy. It's not their imagination. Unlike ...

Medically reviewed by Doru Paul, MD To confirm a psoriasis diagnosis, your healthcare provider will check your skin and scalp ...

and prevents complications like psoriatic arthritis. National Psoriasis Foundation. Pustular psoriasis. National Psoriasis Foundation. Erythrodermic psoriasis. National Psoriasis Foundation. Plaque ...

Alvotech (NASDAQ:ALVO – Get Free Report) will announce its earnings results after the market closes on Wednesday, November ...

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

Treatment with IV secukinumab led to rapid improvements in the signs and symptoms of PsA, which were maintained through 52 weeks.

plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.

Study authors examined the use of artificial intelligence in machine learning models for the assessment of psoriasis severity, as well as identified future research needs.